Abstract
(2016). Cost-effectiveness of lenalidomide plus dexamethasone vs bortezomib plus melphalan and prednisone in transplant-ineligible US patients with newly-diagnosed multiple myeloma. Journal of Medical Economics: Vol. 19, No. 3, pp. 243-258.

This publication has 44 references indexed in Scilit: